Germany
Japan
United Kingdom
China
Antibodies
View as table Download
MEK1 (MAP2K1) (N-term) rabbit polyclonal antibody, Purified
| Applications | IF, IHC, WB |
| Reactivities | Human, Mouse, Rat, Xenopus |
| Immunogen | MAP2K1 antibody was raised against synthetic peptide derived from sequence near the amino-terminus of human MEK1, conjugated to KLH |
Rabbit Polyclonal Anti-QSOX1 Antibody
| Applications | WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Immunogen | QSOX1 antibody was raised against a 17 amino acid peptide near the center of human QSOX1. |
Rabbit Polyclonal Antibody against MAP2K1 (S217)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Immunogen | This MEK1(MAP2K1) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 196-225 amino acids from human MEK1(MAP2K1). |
Rabbit Polyclonal MEK1 Antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1 |
Rabbit Polyclonal MEK1/2 Antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1/2 |
Rabbit Polyclonal MEK1/2 Antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1/2 |
Rabbit Polyclonal MEK1 (Thr291) Antibody (Phospho-specific)
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1 around the phosphorylation site of Threonine 291 |
| Modifications | Phospho-specific |
Rabbit Polyclonal MEK1/2 (Ser217) Antibody (Phospho-specific)
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1/2 around the phosphorylation site of Serine 217 |
| Modifications | Phospho-specific |
Rabbit Polyclonal MEK1/2 (Ser221) Antibody (Phospho-specific)
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | The antiserum was produced against A synthesized peptide derived from human MEK1/2 around the phosphorylation site of Serine 221 |
| Modifications | Phospho-specific |
USD 465.00
2 Weeks
MEK1 (MAP2K1) (incl. pos. control) mouse monoclonal antibody, clone 9G3, Purified
| Applications | ELISA, WB |
| Reactivities | Canine, Human, Mouse, Rat |
Rabbit anti MEK1/2(pS218/S222) Polyclonal Antibody
| Applications | Dot, WB |
| Reactivities | Human, Mouse, Rat |
| Immunogen | A synthetic peptide surrounding the epitope –SMANS- with double phosphorylation sites Ser218 and Ser222. This sequence is identical among human, rat, mouse, chicken. |
MEK1 (MAP2K1) (+MAP2K2) rabbit polyclonal antibody, Aff - Purified
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
MEK1 (MAP2K1) pSer218 rabbit polyclonal antibody, Aff - Purified
| Applications | IHC |
| Reactivities | Human, Mouse, Rat |
MEK1 (MAP2K1) pSer222 rabbit polyclonal antibody, Aff - Purified
| Applications | IHC |
| Reactivities | Human, Mouse, Rat |
MEK1 (MAP2K1) rabbit polyclonal antibody, Aff - Purified
| Applications | IHC |
| Reactivities | Human, Mouse, Rat |
MEK1 (MAP2K1) rabbit polyclonal antibody, Aff - Purified
| Applications | IHC |
| Reactivities | Human, Mouse, Rat |
Rabbit Anti-MEK1/2 (Ser218,222) Antibody (Phospho-Specific)
| Applications | WB |
| Reactivities | Mouse |
| Conjugation | Unconjugated |
| Immunogen | Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser218/222 conjugated to KLH |
| Modifications | Phospho-specific |
Rabbit Anti-MEK1 (Thr292) Antibody (Phospho-Specific)
| Applications | WB |
| Reactivities | recombinant |
| Conjugation | Unconjugated |
| Immunogen | Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr292 conjugated to KLH |
| Modifications | Phospho-specific |
Rabbit Anti-MEK1 (Thr386) Antibody (Phospho-Specific)
| Applications | WB |
| Reactivities | Human, Rat |
| Conjugation | Unconjugated |
| Immunogen | Synthetic phospho-peptide corresponding to amino acid residues surrounding Thr386 conjugated to KLH |
| Modifications | Phospho-specific |
Rabbit Polyclonal MEK1 Antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat, Bovine, Canine, Chicken, Drosophila |
| Conjugation | Unconjugated |
| Immunogen | A portion of amino acids 200-250, containing phospho serine residues at positions 218 and 222, of human MEK1 was used as the immunogen. |
Rabbit anti Mek1 Polyclonal Antibody
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Active filters
Target Symbol
- MAP2K1
Filter by
Category
Reactivities
Applications
Antibody Hosts
Isotypes
Clonalities
Conjugates
Knockout (KO) Validation
Modifications
Assay Types
Assay Platforms
Pathways
- Acute myeloid leukemia (237)
- B cell receptor signaling pathway (237)
- Bladder cancer (237)
- Chemokine signaling pathway (237)
- Chronic myeloid leukemia (237)
- Colorectal cancer (237)
- Dorso-ventral axis formation (237)
- Endometrial cancer (237)
- ErbB signaling pathway (237)
- Fc epsilon RI signaling pathway (237)
- Fc gamma R-mediated phagocytosis (237)
- Focal adhesion (237)
- Gap junction (237)
- Glioma (237)
- GnRH signaling pathway (237)
- Insulin signaling pathway (237)
- Long-term depression (237)
- Long-term potentiation (237)
- MAPK signaling pathway (237)
- Melanogenesis (237)
- Melanoma (237)
- Natural killer cell mediated cytotoxicity (237)
- Neurotrophin signaling pathway (237)
- Non-small cell lung cancer (237)
- Oocyte meiosis (237)
- Pancreatic cancer (237)
- Pathways in cancer (237)
- Prion diseases (237)
- Progesterone-mediated oocyte maturation (237)
- Prostate cancer (237)
- Regulation of actin cytoskeleton (237)
- Renal cell carcinoma (237)
- T cell receptor signaling pathway (237)
- Thyroid cancer (237)
- Toll-like receptor signaling pathway (237)
- VEGF signaling pathway (237)
- Vascular smooth muscle contraction (237)